Revolution Medicines, Inc. (RVMD)

NASDAQ

$78.98

+$0.06 (0.08%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$78.17$79.95

Open $78.43

52 Week Range

$29.17$81.49

Previous Close $78.92

Market Cap15.27B

Volume2.42M

Avg Volume2.24M

P/E (TTM)-15.55

EPS (TTM)$-5.08

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Revolution Medicines, Inc.

NOV52025

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Source: GlobeNewsWire•40 days ago

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated RASolute 304, a Phase 3 clinical trial of...

NOV42025

Revolution Medicines to Participate in November 2025 Investor Conferences

Source: GlobeNewsWire•41 days ago

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A....

OCT292025

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

Source: GlobeNewsWire•47 days ago

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financ...

OCT272025

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

Source: GlobeNewsWire•50 days ago

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Dru...

OCT222025

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

Source: GlobeNewsWire•54 days ago

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for ...

OCT162025

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Source: GlobeNewsWire•60 days ago

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Dru...

SEP292025

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

Source: GlobeNewsWire•78 days ago

REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan S...